Opzelura

What Is Opzelura and What Is It Used For?

Opzelura (ruxolitinib cream 1.5%) is a topical Janus kinase (JAK) inhibitor used to treat non-segmental vitiligo with facial involvement in adults and adolescents aged 12 years and older. It works by blocking JAK1 and JAK2 signalling pathways in the skin, reducing the immune-mediated destruction of melanocytes and allowing the skin to regain its natural pigmentation.

Vitiligo is a chronic autoimmune skin condition affecting approximately 0.5–2% of the global population, with an estimated 65–95 million people affected worldwide. The condition is characterised by the progressive loss of skin pigmentation, resulting in distinctive white or light-pink patches on the skin. These patches occur when melanocytes – the cells responsible for producing the pigment melanin – are destroyed by the body's own immune system.

The autoimmune process underlying vitiligo involves aberrant activation of the JAK-STAT signalling pathway, particularly through interferon-gamma (IFN-γ) signalling. In vitiligo, T lymphocytes (specifically CD8+ cytotoxic T cells) produce excessive amounts of IFN-γ, which signals through the JAK1/JAK2 pathway to upregulate chemokines such as CXCL9 and CXCL10. These chemokines recruit additional immune cells to the skin, creating a self-perpetuating cycle of melanocyte destruction.

Ruxolitinib, the active ingredient in Opzelura, is a potent and selective inhibitor of JAK1 and JAK2. When applied topically to depigmented skin areas, it blocks the JAK-STAT signalling cascade at the local level. By interrupting IFN-γ signalling and reducing the production of CXCL9 and CXCL10, ruxolitinib decreases the recruitment and activation of cytotoxic T cells that are attacking melanocytes. This allows surviving melanocyte stem cells to regenerate, differentiate, and produce melanin, gradually restoring the skin's natural colour.

Opzelura was evaluated in two pivotal phase III clinical trials, TRuE-V1 and TRuE-V2, which enrolled over 600 patients with non-segmental vitiligo affecting the face and other body areas. In these trials, approximately 30% of patients treated with ruxolitinib cream achieved at least 75% improvement in their Facial Vitiligo Area Scoring Index (F-VASI75) at 24 weeks, compared to approximately 10% of patients receiving the vehicle (placebo cream). Results continued to improve with continued treatment up to 52 weeks and beyond.

What Should You Know Before Using Opzelura?

Before using Opzelura, inform your doctor about all medical conditions, current medications, and whether you are pregnant, breastfeeding, or planning to become pregnant. Opzelura is contraindicated during pregnancy and breastfeeding and should not be used in children under 12 years of age.

Contraindications

You should not use Opzelura if any of the following apply:

• Allergy to ruxolitinib or any of the other ingredients in the cream (listed in the “What Does Opzelura Contain?” section below)
• Pregnancy – the safety of topical ruxolitinib during pregnancy has not been established
• Breastfeeding – it is not known whether ruxolitinib passes into breast milk after topical application, and potential effects on nursing infants are unknown

Warnings and Precautions

Talk to your doctor or pharmacist before using Opzelura. There are several important precautions to keep in mind when using this medication:

• Do not apply on mucous membranes: Opzelura must not be used on the lips, in the eyes, mouth, or vagina. If the cream accidentally comes into contact with these areas, it should be carefully wiped off and/or rinsed away with water
• Body surface area limitation: The cream must not be applied to more than 10% of the total body surface area. This is an area equivalent to approximately ten times the size of your palm (including fingers). Exceeding this limit may increase systemic absorption and the risk of side effects
• Immunosuppressive effects: Although systemic absorption from topical application is low, ruxolitinib is a JAK inhibitor with immunosuppressive properties. Discuss with your doctor if you have a weakened immune system, active infections, or a history of serious infections
• Sun protection: Depigmented skin is more sensitive to ultraviolet radiation. Use appropriate sun protection measures, including broad-spectrum sunscreen and protective clothing, especially on treated areas

Children Under 12 Years

Opzelura should not be given to children under 12 years of age. The safety and efficacy of ruxolitinib cream have not been studied in this age group. Clinical trials included adolescents aged 12–17 years, and the approved indication covers adults and adolescents from 12 years of age.

Pregnancy and Breastfeeding

Opzelura must not be used during pregnancy or breastfeeding, as the safety of topical ruxolitinib has not been studied in these populations. The potential risks to the developing foetus or nursing infant are unknown.

If you are a woman of childbearing potential, you must use effective contraception during treatment with Opzelura and for at least 4 weeks after the last application. If you discover that you are pregnant while using Opzelura, stop the treatment immediately and contact your doctor.

It is not known whether ruxolitinib passes into breast milk when applied topically. Given the potential for adverse effects in breastfed infants, Opzelura should not be used while breastfeeding. You may resume breastfeeding approximately 4 weeks after the last application of Opzelura.

Driving and Operating Machinery

Opzelura is unlikely to affect your ability to drive or operate machinery. As a topical cream with minimal systemic absorption, it does not typically cause dizziness, drowsiness, or other central nervous system effects that might impair your ability to perform these activities.

Important Information About Excipients

Opzelura contains several excipients that may cause reactions in sensitive individuals:

• Propylene glycol (E1520): Contains 150 mg per gram of cream, which may cause skin irritation in some people
• Cetyl alcohol and stearyl alcohol: May cause local skin reactions such as contact dermatitis
• Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate: May cause allergic reactions, which may be delayed
• Butylated hydroxytoluene (E321): May cause local skin reactions (e.g. contact dermatitis), or may be irritating to the eyes and mucous membranes
• Polysorbate 20: May cause allergic reactions in susceptible individuals

How Does Opzelura Interact with Other Drugs?

Opzelura should not be used simultaneously with other topical medications on the same skin area, as such combinations have not been studied. After applying Opzelura, wait at least 2 hours before applying any other medication, sunscreen, or moisturiser to the treated area.

Because Opzelura is a topical cream with limited systemic absorption, the potential for significant drug interactions with oral or injected medications is considered low. However, certain precautions should still be observed to ensure safe and effective use.

Topical Product Interactions

The most important interaction consideration for Opzelura relates to other topical products applied to the same skin area. The concurrent use of Opzelura with other topical medications has not been studied, and applying multiple products to the same area could potentially alter the absorption, efficacy, or safety profile of Opzelura or the other product.

Systemic Drug Considerations

While significant systemic drug interactions are unlikely due to the topical route of administration, patients should inform their doctor about all medications they are taking, including:

• Oral JAK inhibitors (e.g. tofacitinib, baricitinib, upadacitinib) – concurrent use with topical ruxolitinib has not been studied and could theoretically increase overall JAK inhibition
• Systemic immunosuppressants (e.g. cyclosporine, methotrexate, azathioprine) – additive immunosuppressive effects may theoretically increase infection risk
• Biologic therapies (e.g. adalimumab, dupilumab, secukinumab) – combined immunomodulatory effects have not been studied with topical ruxolitinib

In clinical trials, no clinically meaningful systemic drug interactions were identified with topical ruxolitinib cream at the recommended dose and body surface area limits. The systemic exposure from topical application is substantially lower than from oral ruxolitinib, which further reduces the likelihood of systemic interactions.

What Is the Correct Dosage of Opzelura?

Apply a thin layer of Opzelura cream twice daily to affected skin areas, with at least 8 hours between applications. Do not apply to more than 10% of total body surface area, and do not use more than two 100-gram tubes per month. Treatment for at least 6 months is recommended for initial assessment.

Always use Opzelura exactly as your doctor or pharmacist has instructed. If you are unsure about any aspect of the treatment, consult your healthcare provider for clarification.

Adults and Adolescents (12 Years and Older)

How to Apply Opzelura

Correct application technique is important for optimal results and safety:

1. Wash your hands before applying the cream
2. Apply a thin layer of cream to the depigmented skin areas only, as directed by your doctor. Do not apply to unaffected skin
3. Wash your hands thoroughly after applying the cream, unless your hands are the treatment area
4. If another person applies the cream for you, they should also wash their hands afterwards
5. Do not wash the treated skin area for at least 2 hours after application
6. Wait at least 2 hours before applying any other topical product (including sunscreen, moisturisers, or other medications) to the same area

Treatment Duration

Vitiligo repigmentation is a gradual process, and patience is essential. Your doctor will determine how long you should continue using Opzelura based on your individual response:

• Minimum recommended duration: 6 months – this is the minimum period before your doctor can meaningfully assess whether the treatment is working for you
• Optimal duration: Treatment may need to continue for over 12 months for satisfactory repigmentation, particularly on areas other than the face
• Facial areas typically respond faster than trunk and extremities
• If you achieve satisfactory repigmentation, discuss with your doctor whether treatment of those specific areas can be stopped
• Contact your doctor if repigmentation decreases after stopping treatment, as resumption may be necessary

Children Under 12 Years

Opzelura is not recommended for children under 12 years of age. The safety and efficacy of ruxolitinib cream have not been established in this age group. If your child has vitiligo, consult a paediatric dermatologist to discuss appropriate treatment options.

Missed Dose

If you forget to apply Opzelura at the scheduled time, apply it as soon as you remember and then continue with your regular dosing schedule. However, if the next application is due within 8 hours, skip the missed dose and apply the cream at the next scheduled time. Do not apply a double amount to make up for a missed application.

Overdose

If you accidentally apply too much cream, simply wipe off the excess. Due to the topical route of administration and body surface area limitations, significant systemic overdose from Opzelura cream is unlikely when used as directed. However, if the cream is accidentally ingested, contact your local poison control centre or seek medical attention immediately.

What Are the Side Effects of Opzelura?

The most commonly reported side effect of Opzelura is acne at the application site, which affects up to 1 in 10 users. Because Opzelura is a topical medication with limited systemic absorption, serious systemic side effects are uncommon. However, certain excipients in the cream may cause local skin reactions in sensitive individuals.

Like all medicines, Opzelura can cause side effects, although not everybody experiences them. The side effect profile of topical ruxolitinib is generally favourable compared to systemic JAK inhibitors, owing to the significantly lower systemic exposure achieved through topical application. In the pivotal TRuE-V1 and TRuE-V2 clinical trials, Opzelura was well tolerated, with most adverse events being mild and localised to the application site.

It is important to distinguish between side effects caused by ruxolitinib itself and those caused by the excipients (inactive ingredients) in the cream formulation. Several excipients, including propylene glycol, cetyl alcohol, stearyl alcohol, methyl parahydroxybenzoate, and butylated hydroxytoluene, have known potential to cause local skin reactions in susceptible individuals.

The safety profile of topical ruxolitinib is considerably more favourable than oral JAK inhibitors. Oral ruxolitinib (Jakavi/Jakafi), used at much higher systemic doses for myelofibrosis and polycythaemia vera, is associated with significant haematological effects (anaemia, thrombocytopenia, neutropenia) and metabolic effects (hypercholesterolaemia). These effects have not been clinically observed with topical Opzelura at recommended doses and within the 10% body surface area limit.

How Should You Store Opzelura?

Store Opzelura at or below 30°C. Keep it out of the sight and reach of children. Once opened, use within 6 months. Do not use after the expiry date printed on the tube and carton.

Proper storage of Opzelura ensures that the cream maintains its stability, efficacy, and safety throughout its shelf life. Follow these storage guidelines carefully:

• Temperature: Store at a maximum of 30°C (86°F). Do not freeze the cream
• After opening: Once the tube has been opened, the cream should be used within 6 months, but not beyond the printed expiry date on the tube and carton
• Expiry date: Check the expiry date (marked “EXP” on the tube and carton) before each use. The expiry date refers to the last day of the stated month
• Keep out of reach: Store the medication out of the sight and reach of children to prevent accidental exposure or ingestion
• Do not dispose improperly: Do not throw unused medication in household waste or flush it down the toilet. Return unused or expired cream to your pharmacy for safe, environmentally responsible disposal

What Does Opzelura Contain?

Each gram of Opzelura cream contains 15 mg of ruxolitinib as the active ingredient, along with several inactive excipients including propylene glycol, cetyl alcohol, dimethicone, and preservatives. The cream is white to off-white in colour and is supplied in 100-gram tubes.

Active Ingredient

The active substance is ruxolitinib. One gram of cream contains 15 mg of ruxolitinib, corresponding to a 1.5% concentration. Ruxolitinib is a selective inhibitor of Janus kinases JAK1 and JAK2, which mediate signalling pathways involved in the autoimmune destruction of melanocytes in vitiligo.

Inactive Ingredients (Excipients)

The other ingredients are:

• Butylated hydroxytoluene (E321)
• Cetyl alcohol
• Dimethicone (E900)
• Disodium edetate (E385)
• Glyceryl stearate
• Paraffin (E905)
• Macrogol (polyethylene glycol)
• Medium-chain triglycerides
• Methyl parahydroxybenzoate (E218)
• Phenoxyethanol
• Polysorbate 20 (E432)
• Propylene glycol (E1520)
• Propyl parahydroxybenzoate
• Purified water
• Stearyl alcohol
• Xanthan gum (E415)

Several of these excipients have the potential to cause local skin reactions or allergic reactions in sensitive individuals. See the “Important Information About Excipients” section above for detailed warnings regarding propylene glycol, cetyl alcohol, stearyl alcohol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, butylated hydroxytoluene, and polysorbate 20.

Cream Appearance and Packaging

Opzelura is a white to off-white cream supplied in aluminium tubes containing 100 grams of cream. Each carton contains one tube. The cream has a smooth, non-greasy texture suitable for application to exposed skin areas, including the face.

Manufacturer

Opzelura is manufactured and marketed by Incyte Biosciences Distribution B.V., Paasheuvelweg 25, 1105 BP Amsterdam, Netherlands. Incyte Corporation, the parent company based in Wilmington, Delaware, USA, is a global biopharmaceutical company focused on the discovery, development, and commercialisation of novel medicines, with particular expertise in oncology and inflammation.

How Does Opzelura Work in the Body?

Opzelura works by selectively inhibiting JAK1 and JAK2 enzymes in the skin, blocking the interferon-gamma signalling pathway that drives the autoimmune destruction of melanocytes in vitiligo. By reducing immune cell recruitment and activity at the site of depigmentation, it allows melanocyte stem cells to regenerate and produce melanin, gradually restoring the skin's natural colour.

To understand how Opzelura works, it is helpful to understand the immunological mechanisms that cause vitiligo. In healthy skin, melanocytes reside in the basal layer of the epidermis and produce melanin, the pigment that gives skin its characteristic colour. In vitiligo, these melanocytes are selectively destroyed by an aberrant autoimmune response.

The key molecular pathway driving melanocyte destruction in vitiligo is the JAK-STAT signalling cascade, particularly the pathway activated by interferon-gamma (IFN-γ). Here is how the disease process unfolds and how ruxolitinib intervenes:

1. Immune activation: In genetically susceptible individuals, a triggering event (which may include stress, sunburn, trauma, or other environmental factors) activates cytotoxic CD8+ T cells that recognise melanocyte-specific antigens
2. IFN-γ release: These activated T cells release IFN-γ, a pro-inflammatory cytokine that signals through the JAK1/JAK2 pathway in skin cells
3. Chemokine production: JAK1/JAK2 activation leads to the phosphorylation of STAT1, which translocates to the nucleus and drives the production of chemokines CXCL9 and CXCL10
4. Immune cell recruitment: CXCL9 and CXCL10 attract additional cytotoxic T cells to the skin, amplifying the immune response against melanocytes
5. Melanocyte destruction: The recruited T cells directly kill melanocytes through perforin-granzyme pathways, leading to progressive depigmentation

Ruxolitinib breaks this cycle by blocking JAK1 and JAK2 at the enzymatic level. By preventing JAK phosphorylation, ruxolitinib stops the downstream activation of STAT1 and the subsequent production of CXCL9 and CXCL10. Without these chemokine signals, the recruitment of destructive T cells to the skin is dramatically reduced, and the immune attack on melanocytes subsides.

With the immune assault halted, melanocyte stem cells residing in hair follicles and at the margins of depigmented patches can begin to proliferate, migrate, and differentiate into mature melanocytes. These regenerated melanocytes resume melanin production, gradually restoring pigmentation to the affected skin. This is why repigmentation often appears first as small “islands” of colour around hair follicles within depigmented patches.

Pharmacokinetic Profile

When applied topically as a 1.5% cream, ruxolitinib is absorbed through the skin in small amounts. The systemic exposure from topical application within the recommended 10% body surface area limit is substantially lower than from therapeutic oral doses of ruxolitinib. This limited systemic absorption is a key safety advantage of the topical formulation, as it provides concentrated local JAK inhibition at the disease site while minimising the risk of systemic immunosuppressive effects.

Ruxolitinib is metabolised primarily by the liver enzyme CYP3A4, similar to the oral formulation. However, given the low systemic levels achieved with topical use, clinically significant drug-drug interactions through CYP3A4 are not expected when Opzelura is used within recommended guidelines.

Frequently Asked Questions About Opzelura